Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | RAB9A | P51151 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719405 | 0.82 | RAB9A (0.64) | LMNAALDH1A1RAB9ANPC1GAA | |
| SCHEMBL29664530 | 0.82 | LMNA (0.74) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL6718898 | 0.81 | POLB (0.66) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL7754151 | 0.77 | LMNA (0.66) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL28780947 | 0.76 | LMNA (0.63) | LMNAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL28897572 | 0.75 | LMNA (0.79) | LMNAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL28443070 | 0.75 | LMNA (0.79) | LMNAALDH1A1MEN1KMT2AGAA | |
| SCHEMBL4016784 | 0.74 | ALDH1A1 (0.73) | LMNAALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL27520438 | 0.74 | MEN1 (0.69) | LMNARAB9AMEN1KMT2AGAA | |
| SCHEMBL27546606 | 0.74 | ALDH1A1 (0.65) | LMNAALDH1A1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | claimed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | claimed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | claimed |
| EP-0888322-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | claimed |
| WO-1997034566-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1997-09-25 | — | — | WO | claimed |
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | FLYNN DANIEL L (US) | 2004-05-06 | — | — | US | disclosed |
| US-6673788-B2 | CONTAINING 2,2,2-TRIFLUORO-1-OXOETHYL GROUPS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-6673784-B1 | HALOSUBSTITUTED ACETOPHENONES AS SELECTIVE HERPESVIRUS PROTEASE INHIBITORS | G. D. SEARLE & CO. | 2004-01-06 | — | — | US | disclosed |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | G. D. SEARLE & CO., CORPORATE PATENT DEPARTMENT | 2003-06-26 | — | — | US | disclosed |
| EP-0888322-B1 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-0888322-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997034566-A2 | ELECTROPHILIC KETONES FOR THE TREATMENT OF HERPESVIRUS INFECTIONS | G.D. SEARLE & CO. (US) | 1997-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087491-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | LMNA 2197/4885ALDH1A1 747/4885RAB9A 1684/4885 |
| US-20030119721-A1 | Electrophilic ketones for the treatment of herpesvirus infections | KHK, HCK, PBK | LMNA 2197/4885ALDH1A1 747/4885RAB9A 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.